 | FEATURED: TARG CEO Interview - Part 1 You are Watching: Targanta's Antibiotic Shows Promise, And Overcomes the Challenges it Faced When Previously Developped at Lilly and InterMune Oritavancin is Targanta's lead compound. Initially developped at Lilly, it was then sold to InterMune, and picked up by Targanta in an equity deal. Mark Leuchtenberger explains the history of the drug, and in doing so faces further probe from Joel Sendek as to the corporate and medical challenges the drug had to face in its earlier days. Mark explains how they were overcome in Targanta's hands, and the true potential of the was drug unlocked. This interview was conducted at the NASDAQ Marketsite, on September 18th, 2008, in New York City. Featuring: * Mark Leuchtenberger, President and CEO, Targanta Therapeutics * Joel Sendek, Managing Director and Senior Biotechnology Analyst, Lazard Capital DISCLAIMER: BIOBUSINESS.TV IS AN INDEPENDENT MEDIA, AND A PLATFORM FOR THE EXCHANGE OF IDEAS AND OPINIONS. BIOBUSINESS.TV STRIVES TO ENHANCE THE QUALITY AND ACCESSIBILITY OF INDUSTRY DATA, AND TO DELIVER INFORMATION THAT INVESTORS AND EXECUTIVES CAN RELY UPON TO MAKE SOUND, INFORMED FINANCIAL AND MANAGERIAL DECISIONS. VIEWERS SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. |
 | Advisory on Treating IPF with Actimmune (May 2007) FDA is alerting healthcare professionals that early results of a clinical study have indicated that patients with idiopathic pulmonary fibrosis (IPF) did not show a survival benefit from being treated with Actimmune, a synthetic version of interferon gamma-1b. Actimmune is not approved to treat IPF. InterMune, the maker of Actimmune, has stopped the study because an interim analysis showed that mortality in IPF patients treated with the drug was 14.5% compared to 12.7% in patients receiving placebo. Reported side effects of treatment included constitutional symptoms, neutropenia, and possibly pneumonia. Although Actimmune has not been approved to treat IPF, some IPF patients may be receiving this product off-label. Healthcare providers should discuss the results of this trial with IPF patients on Actimmune and should carefully consider whether to continue treatment with the drug. FDA is evaluating the study results and will notify healthcare providers if the review reveals additional important information. Additional Information: FDA MedWatch Safety Alert. Actimmune (Interferon Gamma 1-b). March 12, 2007. http://www.fda.gov/medwatch/safety/2007/safety07.htm#Actimmune |
 | Now's the time for small-cap stocks * Baird Small-Cap Healthcare Conference * Video: Intermune CMO discusses Roche partnership * Cerus CEO explains their intercept blood system |
العربية
中国
Français
Deutsch
Ελληνική
हिन्दी
Italiano
日本語
Português
Русский
Español
